Search research articles
Contact Us
Filters
Showing results (1-10 of 131) with videos related to
Page
of 14
Sort By:
Expert Opinion on Drug Metabolism & Toxicology
|
January 6, 2021
Exploring pharmacogenetics of paclitaxel- and docetaxel-induced peripheral neuropathy by evaluating the direct pharmacogenetic-pharmacokinetic and pharmacokinetic-neuropathy relationships
Daniel L Hertz
Pharmacogenomics
|
July 11, 2013
Germline pharmacogenetics of paclitaxel for cancer treatment
Daniel L Hertz
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 15, 2022
Assessment of the Clinical Utility of Pretreatment <i>DPYD</i> Testing for Patients Receiving Fluoropyrimidine Chemotherapy
Daniel L Hertz
The Pharmacogenomics Journal
|
August 10, 2019
Concerns regarding use of patient-reported outcomes in biomarker studies of chemotherapy-induced peripheral neuropathy
Daniel L Hertz
Current Opinion in Supportive and Palliative Care
|
December 21, 2023
Incidence, description, predictors, and consequences of persistent taxane-induced peripheral neuropathy
Daniel L Hertz
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 10, 2023
Reply to H.S. Hochster
Daniel L Hertz
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 8, 2020
Including DPYD on Cancer Genetic Panels to Prevent Fatal Fluoropyrimidine Toxicity
Daniel L Hertz, Vaibhav Sahai
Annual Review of Medicine
|
November 12, 2014
Pharmacogenetics of cancer drugs
Daniel L Hertz, James Rae
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 3, 2026
Ending the Controversy Around Pretreatment Dihydropyrimidine Dehydrogenase (DPD/<i>DPYD</i>) Testing Heightens the Controversy Over Appropriate Fluoropyrimidine Dosing
Daniel L Hertz, Alan P Venook
Handbook of Experimental Pharmacology
|
October 17, 2022
Chemotherapy-Induced Peripheral Neuropathy
Ciao-Sin Chen, Daniel L Hertz
Page
of 14
Search research articles
Search
Showing results (1-10 of 131) with videos related to
Sort By:
Page
of 14
Expert Opinion on Drug Metabolism & Toxicology
|
January 6, 2021
Exploring pharmacogenetics of paclitaxel- and docetaxel-induced peripheral neuropathy by evaluating the direct pharmacogenetic-pharmacokinetic and pharmacokinetic-neuropathy relationships
Daniel L Hertz
Pharmacogenomics
|
July 11, 2013
Germline pharmacogenetics of paclitaxel for cancer treatment
Daniel L Hertz
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 15, 2022
Assessment of the Clinical Utility of Pretreatment <i>DPYD</i> Testing for Patients Receiving Fluoropyrimidine Chemotherapy
Daniel L Hertz
The Pharmacogenomics Journal
|
August 10, 2019
Concerns regarding use of patient-reported outcomes in biomarker studies of chemotherapy-induced peripheral neuropathy
Daniel L Hertz
Current Opinion in Supportive and Palliative Care
|
December 21, 2023
Incidence, description, predictors, and consequences of persistent taxane-induced peripheral neuropathy
Daniel L Hertz
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 10, 2023
Reply to H.S. Hochster
Daniel L Hertz
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 8, 2020
Including DPYD on Cancer Genetic Panels to Prevent Fatal Fluoropyrimidine Toxicity
Daniel L Hertz, Vaibhav Sahai
Annual Review of Medicine
|
November 12, 2014
Pharmacogenetics of cancer drugs
Daniel L Hertz, James Rae
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 3, 2026
Ending the Controversy Around Pretreatment Dihydropyrimidine Dehydrogenase (DPD/<i>DPYD</i>) Testing Heightens the Controversy Over Appropriate Fluoropyrimidine Dosing
Daniel L Hertz, Alan P Venook
Handbook of Experimental Pharmacology
|
October 17, 2022
Chemotherapy-Induced Peripheral Neuropathy
Ciao-Sin Chen, Daniel L Hertz
Page
of 14